Lu-177-Labeled Zirconia Particles for Radiation Synovectomy

Polyák, András; Nagy, Lı́via; Drotár, Eszter; Dabasi, Gabriella; Jóba, R. P.; Pöstényi, Zita; Mikołajczak, Renata; Bóta, Attila

doi:10.1089/cbr.2015.1881

Cited by 9 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radiopharmaceutical activity of the 117m Sn colloid used in this study (92.5MBq) equaled the maximum projected activity likely to be used for treatment of elbow osteoarthritis. This dose was approximately half that of 177 Lu administered by Polyak et al for radiosynoviorthesis of the tarsus in a Cavalier King Charles Spaniel, but similar to the dose of 186 Re used by Liepe for ankle, wrist, or shoulder radiosynoviorthesis in human patients with rhematoid arthritis . Other radiation doses used for radiosynoviorthesis in humans have varied widely, ranging from 15 MBq of 186 Re for fingers and toes to 925 MBq of 188 Re for knees .…”

Section: Discussionmentioning

confidence: 62%

“…Polyak et al used intra‐articular 177 Lu‐labeled zirconia colloid to successfully treat a dog with naturally occurring hock osteoarthritis . Lutetium‐177, like 90 Y, 186 Re, and 169 Er, is a beta emitter.…”

Section: Discussionmentioning

confidence: 99%

“…Radiosynoviorthesis has not been widely used in animals. Polyak et al used lutetium‐177 ( 177 Lu)‐labeled zirconia colloid to successfully treat osteoarthritis in a dog . Doerr et al used a patented preparation of a 117m Sn homogeneous colloid to perform radiosynoviorthesis in rats with induced rheumatoid arthritis and induced osteoarthritis .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intraarticular injection of a Tin‐117 m radiosynoviorthesis agent in normal canine elbows causes no adverse effects

Lattimer

Selting

Lunceford

et al. 2019

Vet Radiology Ultrasound

View full text Add to dashboard Cite

This longitudinal prospective exploratory study used serial measurements in five dogs to evaluate safety and retention of a tin-117 m ( 117m Sn) colloid after intra-articular injection in normal elbow joints. Each dog was deemed healthy based on physical examination, laboratory results, and radiographic evaluation of both elbows. While anesthetized, each received an MRI of both elbows, followed by fluorine-18 fluorodeoxyglucose positron emission tomography scans of both elbow joints and associated lymph nodes. Joint fluid (0.5-1.0 mL) was withdrawn aseptically from the left elbow joint, followed by intra-articular injection of 117m Sn colloid (92.5 MBq; 1-1.5 ml). Postinjection assessments included blood counts, serum chemistry panels, urinalyses, radiographs, joint fluid analyses, MRI/positron emission tomography scans, scintigraphy, and biodistribution scans. On day 45-47, each dog was euthanized and a complete postmortem examination was performed. Tissue samples were submitted for histopathology and radioisotope retention studies.Left elbow joints were decalcified and sectioned for future autoradiography. Scintigraphy, 1 day after injection, indicated slight radioisotope escape from the joint to regional lymph nodes. Serial blood, urine, feces, and organ counts indicated >99.1% of the 117m Sn activity was retained in the joint for 45-47 days. Radiation output levels were below patient release levels the day following injection. Maximum standard uptake value for the injected joint decreased. Joint fluid cytology was unchanged. No dog exhibited lameness during the study. Absence of joint damage and lack of systemic effects after injection of the 117m Sn colloid in normal canine elbow joints indicate that this agent may be safely used for radiosynoviorthesis in dogs with osteoarthritis. K E Y W O R D Sarthritis, radiation therapy, radioisotope, synovectomy

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intraarticular injection of a Tin‐117 m radiosynoviorthesis agent in normal canine elbows causes no adverse effects

Lattimer

Selting

Lunceford

et al. 2019

Vet Radiology Ultrasound

View full text Add to dashboard Cite

show abstract

“…Despite its many advantages, RSO is seldom performed in veterinary medicine, with limited reports including use of 177 lutetium-labeled zirconia in dogs and 117m Sn homogeneous colloid in rats. [24][25][26] In a recent prospective safety study of 5 dogs, blood, urine, feces, and organ scintigraphy counts showed that >99% of 117m Sn activity was retained in the elbow joint for approximately 6-7 weeks. 23 There were no adverse effects, and post-mortem evaluation revealed no joint damage.…”

Section: Introductionmentioning

confidence: 99%

Prospective Clinical Evaluation of Intra-Articular Injection of Tin-117m (117mSn) Radiosynoviorthesis Agent for Management of Naturally Occurring Elbow Osteoarthritis in Dogs: A Pilot Study

Aulakh¹,

Lopez²,

Hudson³

et al. 2021

VMRR

View full text Add to dashboard Cite

Purpose To evaluate the clinical effects of an intra-articular injection of 117m Sn-colloid for management of canine grade 1 or 2 elbow osteoarthritis (OA). Patients and Methods This was a prospective study in 23 dogs with grade 1 or 2 elbow OA. An orthopedic examination and elbow radiographs were performed to confirm the presence of OA. Dogs were randomly assigned to receive unilateral intra-articular (IA) injection of low-dose (LD: 1.0mCi, n =8), medium-dose (MD: 1.75mCi, n =6), or high-dose (HD: 2.5mCi, n =9) of 117m Sn-colloid. The primary outcome measure was peak vertical force (PVF) from force-plate gait analysis and secondary outcome measures included the Canine Brief Pain Inventory score (CBPI) and elbow goniometry. The CBPI was evaluated at pretreatment and then monthly post treatment for 1 year, and goniometry and PVF were evaluated at pretreatment, and at 1, 3, 6, 9 and 12 months post treatment. Results PVF improved at 3, and 9 months compared to pretreatment values in the HD group. CBPI scores improved at most of the time points in all dose groups. There was no significant difference in elbow goniometry between treated and untreated elbows. There were no self-reports of any adverse effects of the injection by the owners and none were noted by the examining veterinarian at the time of regularly scheduled re-evaluations. Conclusion 117m Sn IA injection was free of any obvious adverse effects, improved CBPI scores, and increased weight bearing in limbs with elbow OA providing preliminary evidence that 117m Sn may be beneficial in the management of elbow OA in dogs. Although 17m Sn appeared to be effective for management of elbow OA in these dogs, this pilot study has inherent limitations; therefore, future studies with larger numbers and with placebo group are needed.

show abstract

“…Similar clinical results are reported in horses, where a dose raging between 5 and 15 Gy has been used to treat degenerative joint diseases (DJD) ( 17 , 18 ). First experiences of local radiation therapy by intra-articular administration of β-emitting radionuclides are reported in dogs, showing improvement in clinical signs and no significant side effects ( 19 , 20 ). Recently, a single-fraction 10 Gy RT protocol has been investigated in five Labrador Retrievers affected by elbow OA, with short-term clinical benefit and improved weight bearing in the affected limb ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

Megavoltage Radiotherapy for the Treatment of Degenerative Joint Disease in Dogs: Results of a Preliminary Experience in an Italian Radiotherapy Centre

et al. 2018

View full text Add to dashboard Cite

The aim of the study was to evaluate the efficacy and toxicity of a low-dose radiotherapy treatment in dogs with osteoarthritis (OA). Inclusion criteria were dogs affected by OA of one or multiple joints, with lameness, previously treated with medical therapy and referred for radiotherapy because of chronic unresponsive pain. After suspension of medical therapy, dogs underwent external beam radiotherapy treatments delivered in three fractions of 2 Gy each. Four of these dogs had one (three dogs) to four (one dog) additional courses of radiation. Medical records were reviewed and follow-up information was collected by clinical recheck and owners interview. Twenty-five dogs matched the inclusion criteria; among them, 21 had one course of RT and 4 underwent multiple treatments, respectively 218, 266, 39, and 1,384 days after the first treatment. Clinical improvement was observed in 92% of patients with median benefit duration of 356 days after the first treatment, and 418 days after the second treatment. No side effects were recorded. In this group of patients, radiotherapy was effective, well tolerated, and repeatable, leading to an improvement of quality of life in dogs with degenerative joint disease unresponsive to medical treatments.

show abstract

Lu-177-Labeled Zirconia Particles for Radiation Synovectomy

Cited by 9 publications

References 13 publications

Intraarticular injection of a Tin‐117 m radiosynoviorthesis agent in normal canine elbows causes no adverse effects

Intraarticular injection of a Tin‐117 m radiosynoviorthesis agent in normal canine elbows causes no adverse effects

Prospective Clinical Evaluation of Intra-Articular Injection of Tin-117m (117mSn) Radiosynoviorthesis Agent for Management of Naturally Occurring Elbow Osteoarthritis in Dogs: A Pilot Study

Megavoltage Radiotherapy for the Treatment of Degenerative Joint Disease in Dogs: Results of a Preliminary Experience in an Italian Radiotherapy Centre

Contact Info

Product

Resources

About